In a study by Cao et al., CAR‐NK targeting both BCMA and GPRC5D had a killing effect on MM cells, and compared with CAR‐T targeting BCMA alone, BCMA/GPRC5D dual‐targeted CAR‐NK cells effectively lysed BCMA‐negative MM cells, improved the survival rate of MM xenografts, and reduced tumor recurrence [41]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.